Ovid Therapeutics (OVID) – Research Analysts’ Recent Ratings Changes

Ovid Therapeutics (NASDAQ: OVID) has recently received a number of price target changes and ratings updates:

• 8/3/2026 – Ovid Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $7.00 to $9.00. They now have an “outperform” rating on the stock.
• 7/25/2026 – Ovid Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/21/2026 – Ovid Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 7/17/2026 – Ovid Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/27/2026 – Ovid Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/13/2026 – Ovid Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.